SEM stock forecast analyzes Select Medical’s healthcare stability amid sector pressures, price at $16.29. Explore SEM stock price trends, earnings results, technical analysis, and if SEM stock is a buy.
Introduction
Select Medical Holdings operates long-term acute care hospitals and inpatient rehab facilities across the U.S. Investors track SEM stock closely after recent analyst downgrades and steady revenue growth. Healthcare stocks navigate reimbursement cuts and labor cost pressures in 2026.
RBC Capital’s price target cut raises questions. This analysis uses last market close data from March 2, 2026.
Latest Stock Price & Trend
SEM stock closed at $16.29 on March 2, 2026, up slightly from $16.00 open within $16.00-$16.52 range. Volume reached 1 million shares during normal trading.
Five-day trend eased 2% amid downgrade news. One-month performance flat around $16.30 levels. Three-month gains held 10% from January lows near $14.80.
Six months mixed with 5% return; year-to-date up 2%. 52-week high $19.54, low $11.65. Sideways trend with mild bearish tilt suggests caution for momentum investors.
Technical Analysis
Support sits at $15.50-$16.00, matching recent lows where shares stabilized. Resistance at $17.00 blocks upside attempts.
RSI around 48 shows neutral momentum—below 30 oversold for potential buys, above 70 overbought warns selloffs. MACD flat, lacking bullish or bearish conviction.
50-day moving average near $16.50 trails 200-day slightly at $16.80; no golden cross (bullish) or death cross active. Volume averages 1.63 million shares steadily.
These basics help beginners spot range-bound opportunities safely.
Analyst Ratings & Price Targets
Three analysts rate SEM stock Buy consensus overall. Average target $16.33 near current price; RBC cut to $16.50 from $19.00 recently.
33% Strong Buy, 33% Buy, 33% Hold ratings noted. Firms praise revenue growth but flag margins. Mixed sentiment advises selectivity for investors.
Insider Activity
Insider buying quiet in recent quarters. Minor sales reported under $1 million total per SEC filings.
Management maintains steady ownership levels. Low activity reflects operational focus over trading signals.
Valuation Analysis
Trailing P/E ratio stands at 21.56x on $0.87 EPS. Forward P/E attractive at 13.53x growth expectations.
Price-to-Sales reasonable with $5.37 billion TTM revenue, up 45.3% YoY. Net income $108.41 million down 60.2%; free cash flow supports $0.25 dividend.
Debt position manageable; cash covers operations. Versus peers like Encompass Health, SEM stock appears fairly valued with 1.53% yield advantage.
Recent Earnings & Catalysts
2024 full-year revenue reached $5.19 billion, up 7.48% YoY. Earnings fell 12.28% to $211.72 million amid cost pressures.
Q4 results showed $1.40 billion revenue, $0.16 EPS down sharply. Next earnings February 19, 2026. Catalysts: Outpatient expansion, cost controls.
Mixed results kept shares range-bound; dividend maintained confidence.
Bullish Case
Aging population drives LTAC demand steadily. Revenue grows 7-10% annually from volume.
1.53% yield attracts income investors. Outpatient services diversify revenue smartly.
Bearish Case
Medicare reimbursement cuts squeeze margins. Labor shortages persist industry-wide.
Net income volatility concerns analysts. Regulatory changes threaten reimbursements.
Market Sentiment & Investor Psychology
Short interest moderate around 4-5%. Options activity balanced without extremes.
Institutions hold majority ownership steadily. Retail favors dividend safety. Sentiment neutral with value orientation.
Short-Term Outlook
RSI neutral supports $15.50-$17.00 range. Volume steady eyes earnings cycle.
Consolidation likely absent surprises.
Medium to Long-Term Outlook
LTAC model benefits demographic tailwinds. Healthcare grows 5% yearly steadily.
Financial position supports dividends; expansions build moat. Hold for yield; accumulate weakness selectively.
FAQ
Is SEM stock a buy right now?
Buy consensus; suits dividend investors.
What is the price target for SEM stock?
$16.33 average; highs $21.00, $16-$22 end-2026.
What are major risks for SEM stock?
Reimbursement cuts, labor costs, earnings volatility.
SEM earnings outlook?
Revenue growth continues; margins pressured.
SEM long term outlook?
Stable on aging population demand.
Suggestions
- Compare with Opendoor stock
- See our LHC Group healthcare forecast
- Read our LTAC sector valuation guide
Conclusion
Hold SEM stock. Reliable revenue growth offsets margin risks—solid income play for patient investors.
Disclaimer: This article is for informational purposes only and not financial advice.